You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

ABIRATERONE ACETATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Abiraterone Acetate patents expire, and what generic alternatives are available?

Abiraterone Acetate is a drug marketed by Amneal Pharms, Apotex, Dr Reddys, Florida, Glenmark Speclt, Hikma, MSN, Mylan, Novugen, Qilu, Rising, Teva Pharms Usa, and Wockhardt Bio Ag. and is included in fifteen NDAs.

The generic ingredient in ABIRATERONE ACETATE is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Abiraterone Acetate

A generic version of ABIRATERONE ACETATE was approved as abiraterone acetate by APOTEX on October 31st, 2018.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ABIRATERONE ACETATE?
  • What are the global sales for ABIRATERONE ACETATE?
  • What is Average Wholesale Price for ABIRATERONE ACETATE?
Drug patent expirations by year for ABIRATERONE ACETATE
Drug Prices for ABIRATERONE ACETATE

See drug prices for ABIRATERONE ACETATE

Recent Clinical Trials for ABIRATERONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Changhai HospitalN/A
Merck Sharp & Dohme LLCPhase 3
Orion Corporation, Orion PharmaPhase 3

See all ABIRATERONE ACETATE clinical trials

Medical Subject Heading (MeSH) Categories for ABIRATERONE ACETATE
Paragraph IV (Patent) Challenges for ABIRATERONE ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
YONSA Tablets abiraterone acetate 125 mg 210308 1 2018-07-23
ZYTIGA Tablets abiraterone acetate 500 mg 202379 1 2017-08-23
ZYTIGA Tablets abiraterone acetate 250 mg 202379 13 2015-04-28

US Patents and Regulatory Information for ABIRATERONE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms ABIRATERONE ACETATE abiraterone acetate TABLET;ORAL 208327-001 Jan 7, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising ABIRATERONE ACETATE abiraterone acetate TABLET;ORAL 208371-001 Feb 25, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glenmark Speclt ABIRATERONE ACETATE abiraterone acetate TABLET;ORAL 209227-001 Oct 16, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys ABIRATERONE ACETATE abiraterone acetate TABLET;ORAL 208416-001 May 18, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan ABIRATERONE ACETATE abiraterone acetate TABLET;ORAL 208446-001 Oct 31, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa ABIRATERONE ACETATE abiraterone acetate TABLET;ORAL 208432-001 Oct 31, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ABIRATERONE ACETATE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Mylan Ireland Limited Abiraterone Mylan abiraterone acetate EMEA/H/C/005368
Abiraterone Mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Authorised yes no no 2021-08-20
Krka, d.d., Novo mesto Abiraterone Krka abiraterone acetate EMEA/H/C/005649
Abiraterone Krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Authorised yes no no 2021-06-24
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.